Pfizer Restructuring May Precede Total Breakup of the Empire

Pfizer is moving forward to internally separate its commercial operations into three business segments. Pfizer said that two business lines will include “Innovative” business lines and a third segment is its “Value” business line. Each of the three segments will include developed markets and emerging markets.

The changes will take place in countries which “do not require a consultation with works councils or unions, and will be implemented in countries that require consultation after the successful conclusion of those processes.” Pfizer will then start providing financial transparency for each of these three business segments. This  is one of those moves that just has all of the earmarks of a corporate break-up, and that is after Pfizer has already disposed of many assets and made acquisitions along the way.

Its two “Innovative” groups will be as follows:

• One will be led by Geno Germano, Group President, Innovative Products Group, and will include products across multiple therapeutic areas that are expected to have market exclusivity beyond 2015. These include Inflammation and Immunology, CV/Metabolic, Neuroscience and Pain, Rare Diseases and Women’s/Men’s Health.
• The second “Innovative” group will be led by Amy Schulman, Group President, Vaccines, Oncology and Consumer Healthcare. Its areas of operation will include Vaccines, Oncology and Consumer Healthcare.

Pfizer shows that each of these businesses will “operate as a separate global business and require distinct specialization in terms of the science, talent, and market approach required to deliver value to consumers and patients.” Does this sound like a break-up proposition is coming yet?

Pfizer’s third segment, the “Value” business segment, is going to be led by John Young, Group President, Value Products Group.  This value group will include products “that generate strong, consistent cash flow, and will be positioned to provide patients access to effective, lower-cost, high-value treatments.” These will include products that have lost their market exclusivity and will include patent-protected products which the company deems to be matured markets which will lose exclusivity through 2015 in most major markets. Biosimilars and current and future established products collaborations will fall in this group as well.

This sure sounds like Pfizer wants to create an established and generics company that is separated from the key R&D and future drug development programs. If that occurs, another change in the list of DJIA components could occur.

Pfizer shares are up 1% at $29.69 in late-Monday trading against a 52-week range of $23.55 to $31.15. Pfizer is a DJIA component and yields about 3.3% for its common stockholders. Here are some of the changes which have been effected over the last decade:

• Pfizer and Warner-Lambert merger (2000);
• Pfizer and Pharmacia merger (2003);
• Pfizer acquires Wyeth (2009);
• Pfizer acquisition of King Pharma (2010);
• Pfizer also sold its Capsugel unit (maker of hard capsules) for almost $2.4 billion to KKR;
• Pfizer in 2013 accepted 405,117,195 shares of its common stock in exchange for the 400,985,000 shares of Zoetis Inc. (NYSE: ZTS), its former animal health unit, owned by Pfizer.

It is very common for companies to acquire their way into dominance. You just have to wonder about how much value was really created when they go down a path of breaking up the company to unlock all that value after the fact.